<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185013</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-301</org_study_id>
    <secondary_id>2016-002761-63</secondary_id>
    <nct_id>NCT03185013</nct_id>
  </id_info>
  <brief_title>REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)</brief_title>
  <acronym>REVEAL 1</acronym>
  <official_title>A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inovio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to
      determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular
      (IM) injection followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women
      with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL)
      (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) associated with human
      papillomavirus (HPV) 16 and/or HPV-18.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for evidence of cervical HSIL on histology as well as evidence of HPV-16 and/or HPV-18 in cervical samples by type-specific HPV testing at the Week 36 visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of Participants with Any Adverse Events (AEs) and Serious Adverse Events (SAEs) Following Investigational Treatment and for the Duration of the Study</measure>
    <time_frame>From baseline to Week 88</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. An SAE is any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Evidence of Cervical HSIL at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for evidence of cervical HSIL on histology at the Week 36 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Evidence of HPV-16 and/or HPV-18 in Cervical Samples at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for evidence of HPV-16 and/or HPV-18 in cervical samples by type-specific HPV testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Evidence of Low Grade Squamous Intraepithelial Lesion (LSIL) or HSIL at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for evidence of LSIL (i.e. slightly abnormal cells on the surface of the cervix) or HSIL (i.e. evidence of cervical intraepithelial neoplasia grade 1 [CIN1], CIN2 or CIN3 on biopsies or excisional treatment) on histology at the Week 36 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Evidence of LSIL or HSIL and No Evidence of HPV-16 and/or HPV-18 at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for evidence of LSIL (i.e. slightly abnormal cells on the surface of the cervix) or HSIL (i.e. evidence of CIN1, CIN2 or CIN3 on biopsies or excisional treatment) on histology and no evidence of HPV-16 and/or HPV-18 by type-specific HPV testing at the Week 36 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Progression of Cervical HSIL to Cervical Carcinoma from Baseline to Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for progression of cervical HSIL to cervical carcinoma from baseline on histology at the Week 36 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations at Week 36</measure>
    <time_frame>At Week 36</time_frame>
    <description>Participants will be evaluated for HPV-16 and/or HPV-18 status in specimens from non-cervical anatomic locations at the Week 36 Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Levels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations</measure>
    <time_frame>At baseline, Week 15, Week 36 and Week 88</time_frame>
    <description>Levels of anti-HPV-16 and anti-HPV-18 antibody concentrations will be measured in serum samples of participants using a standardized assay at baseline, Week 15, Week 36, and Week 88.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Interferon-Gamma Response Magnitude</measure>
    <time_frame>At baseline, Week 15, Week 36 and Week 88</time_frame>
    <description>Peripheral blood mononuclear cells (PBMCs) will be isolated from whole blood samples collected at baseline, Week 15, Week 36 and Week 88. Assessment of cellular immune activity will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Flow Cytometry Response Magnitude</measure>
    <time_frame>At baseline, Week 15</time_frame>
    <description>Assessment of cellular immune activity will be performed using flow cytometry.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Cervical Dysplasia</condition>
  <condition>Cervical High Grade Squamous Intraepithelial Lesion (HSIL)</condition>
  <arm_group>
    <arm_group_label>VGX-3100 + EP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM injections with VGX-3100 followed by electroporation (EP) using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + EP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IM injections with matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VGX-3100</intervention_name>
    <description>1 milliLiter (mL) VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.</description>
    <arm_group_label>VGX-3100 + EP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.</description>
    <arm_group_label>Placebo + EP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electroporation (EP)</intervention_name>
    <description>Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.</description>
    <arm_group_label>VGX-3100 + EP</arm_group_label>
    <arm_group_label>Placebo + EP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18 years and above

          -  Confirmed cervical infection with HPV types 16 and/or 18 at screening

          -  Cervical tissue specimen/slides provided to Study Pathology Adjudication Committee for
             diagnosis scheduled to be collected within 10 weeks prior to anticipated date of first
             dose of study drug

          -  Confirmed histologic evidence of cervical HSIL at screening

          -  Must be judged by Investigator to be an appropriate candidate for the
             protocol-specified procedure required at Week 36

          -  With respect to their reproductive capacity must be post-menopausal or surgically
             sterile or willing to use a contraceptive method with failure rate of less than 1% per
             year when used consistently and correctly from screening until Week 36

          -  Normal screening electrocardiogram (ECG)

        Exclusion Criteria:

          -  Microscopic or gross evidence of adenocarcinoma-in-situ (AIS), high grade vulvar,
             vaginal, or anal intraepithelial neoplasia or invasive cancer in any histopathologic
             specimen at screening

          -  Cervical lesion(s) that cannot be fully visualized on colposcopy

          -  History of endocervical curettage (ECC) which showed cervical HSIL indeterminate, or
             insufficient for diagnosis

          -  Treatment for cervical HSIL within 4 weeks prior to screening

          -  Pregnant, breastfeeding or considering becoming pregnant during the study

          -  History of previous therapeutic HPV vaccination

          -  Immunosuppression as a result of underlying illness or treatment

          -  Receipt of any non-study, non-live vaccine within 2 weeks of Day 0

          -  Receipt of any non-study, live vaccine within 4 weeks of Day 0

          -  Current or history of clinically significant, medically unstable disease or condition
             which, in the judgment of the investigator, would jeopardize the safety of the
             participant, interfere with study assessments or endpoint evaluation, or otherwise
             impact the validity of the study results

          -  Presence of acute or chronic bleeding or clotting disorder that would contraindicate
             IM injections, or use of blood thinners within 2 weeks of Day 0

          -  Participation in an interventional study with an investigational compound or device
             within 30 days of signing informed consent

          -  Less than two acceptable sites available for IM injection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prakash Bhuyan, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Inovio Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inovio Call Center</last_name>
    <phone>267-440-4237</phone>
    <email>clinical.trials@inovio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Coastal Clinical Research Inc</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Anna May</last_name>
      <phone>251-441-1984</phone>
      <phone_ext>134</phone_ext>
      <email>annam@ccr-research.com</email>
    </contact>
    <investigator>
      <last_name>Danilo Herrera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesa Obstetricians and Gynecologist</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Jamie Lambert</last_name>
      <phone>602-363-8105</phone>
      <email>jlambert@cactusclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Ernesto Gomez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Health Research</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Danielle Gincastro</last_name>
      <phone>480-305-7423</phone>
      <email>daniellegincastro@momdoc.com</email>
    </contact>
    <investigator>
      <last_name>Micah Harris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research-Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Nichele Bonnett</last_name>
      <phone>520-546-4700</phone>
      <email>nlpollock@visionstucson.com</email>
    </contact>
    <investigator>
      <last_name>Cynthia Goldberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group, LLC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Kristine Sykes</last_name>
      <phone>727-724-9730</phone>
      <email>kristye@xxresearch.com</email>
    </contact>
    <investigator>
      <last_name>Edward Zbella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altus Research</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Ixsa Morel</last_name>
      <phone>561-641-0404</phone>
      <phone_ext>105</phone_ext>
      <email>imorel@altusresearch.com</email>
    </contact>
    <investigator>
      <last_name>Samuel Lederman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salom and Tangir LLC</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Suzette Zamora</last_name>
      <phone>954-602-9723</phone>
      <phone_ext>312</phone_ext>
      <email>szamora@salomtangir.org</email>
    </contact>
    <investigator>
      <last_name>Jacob Tangir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Julie Andrew</last_name>
      <phone>561-478-3177</phone>
      <email>jandrew@cctllc.net</email>
    </contact>
    <investigator>
      <last_name>Ronald Ackerman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Angela Goebel</last_name>
      <phone>706-721-2535</phone>
      <email>agoebel@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Daron Ferris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WR-Mount Vernon Clinical Research</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Jessie Park</last_name>
      <phone>404-843-4410</phone>
      <email>jpark@mtvcr.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Blank</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hutchinson Clinic</name>
      <address>
        <city>Hutchinson</city>
        <state>Kansas</state>
        <zip>67502-1131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Juan Morales</last_name>
      <phone>620-694-4123</phone>
      <email>juan.morales@qcareresearch.com</email>
    </contact>
    <investigator>
      <last_name>Christine Sanders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator John Moore</last_name>
      <phone>913-588-6287</phone>
      <email>jmoore20@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Ault</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praetorian Pharmaceutical Research, LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Lyza Murillo</last_name>
      <phone>504-934-8093</phone>
      <email>lyza@praetorianpharmaceutical.com</email>
    </contact>
    <investigator>
      <last_name>Clifton Nicholson-Uhl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedPharmics</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Melissa Spedale</last_name>
      <phone>504-304-7197</phone>
      <phone_ext>7</phone_ext>
      <email>melissaspedale@medpharmics.com</email>
    </contact>
    <investigator>
      <last_name>Robert Jeanfreau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saginaw Valley Medical Research Group LLC</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Jaclyn Muter</last_name>
      <phone>989-497-5851</phone>
      <email>jmuter@womensob.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Minnec</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research Norfolk</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Pamela Chandler</last_name>
      <phone>402-371-0797</phone>
      <email>pchandler@mcrmed.com</email>
    </contact>
    <investigator>
      <last_name>Keith Vrbicky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Yanille Taveras</last_name>
      <phone>973-972-6262</phone>
      <email>taveraya@njms.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Einstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Reena Vattakalam</last_name>
      <phone>212-342-6895</phone>
      <email>rmv2110@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ana Tergas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Pelvic Pain and Minimally Invasive Gynecologic Surgery PC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10038</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Stethanie Jacobs</last_name>
      <phone>646-290-9560</phone>
      <email>stethanie@nywhr.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth Levey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suffolk Obstetrics and Gynecology</name>
      <address>
        <city>Port Jefferson</city>
        <state>New York</state>
        <zip>11777</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Christine Riggio</last_name>
      <phone>631-656-4060</phone>
      <email>criggio@prohealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Lance Edwards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Women's Research and Wellness Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Scarlet Dial</last_name>
      <phone>919-251-9223</phone>
      <email>scarlet@cwrwc.com</email>
    </contact>
    <investigator>
      <last_name>Andrea Lukes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607-7514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Monique Carignan</last_name>
      <phone>919-788-4465</phone>
      <email>monique.carignan@unifiedhc.com</email>
    </contact>
    <investigator>
      <last_name>Littleton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site manager Lisa Cumming</last_name>
      <phone>336-397-3707</phone>
      <email>lcumming@lyndhurstgyn.com</email>
    </contact>
    <investigator>
      <last_name>Robert Parker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Trynisha Cheadle</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>46205</phone_ext>
      <email>Trynisha-Cheadle@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Pharmaceutical Research, Inc.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Kayla Peay</last_name>
      <phone>864-770-0890</phone>
      <email>kpeay@vitalinkresearch.com</email>
    </contact>
    <investigator>
      <last_name>David Godwin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magnolia Ob/Gyn Research Center, LLC</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Ann Scandariato</last_name>
      <phone>843-449-0803</phone>
      <email>ann@magnoliaobgyn.com</email>
    </contact>
    <investigator>
      <last_name>Helena Kirkpatrick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chattanooga's Program In Women's Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator Stephen DePasquale</last_name>
      <phone>423-266-3636</phone>
      <email>stephen.depasquale@erlanger.org</email>
    </contact>
    <investigator>
      <last_name>Stephen DePasquale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chattanooga Medical Research Inc</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Jonathan Mayberry</last_name>
      <phone>423-648-7794</phone>
      <email>smayberry@chattmedresearch.com</email>
    </contact>
    <investigator>
      <last_name>Kirk Brody</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Physician Group</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Sirena Tucker</last_name>
      <phone>901-276-3222</phone>
      <email>sirenatucker@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Belvia Carter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Woman's Hospital of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Lori Wink</last_name>
      <phone>713-790-8500</phone>
      <email>lori.wink@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Sandra Hurtado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BI Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Anusha Chunduri</last_name>
      <phone>281-944-3610</phone>
      <email>anusha@clinicalrc.net</email>
    </contact>
    <investigator>
      <last_name>Kourtney Sims</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Group For Women</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator April Rush</last_name>
      <phone>757-471-3375</phone>
      <phone_ext>1</phone_ext>
      <email>tcrrusch@cox.net</email>
    </contact>
    <investigator>
      <last_name>Mohamad Parva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multicare Health System</name>
      <address>
        <city>Covington</city>
        <state>Washington</state>
        <zip>98042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Leann Harris</last_name>
      <phone>253-545-5839</phone>
      <email>lmharris@multicare.org</email>
    </contact>
    <investigator>
      <last_name>James Rice</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Spokane Women's Clinic</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Kathy Ziehnert</last_name>
      <phone>509-777-1333</phone>
      <email>ziehnek@nwrm.com</email>
    </contact>
    <investigator>
      <last_name>Ronald Hardy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava, prispevkova organizace</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sub-Investigator Tibor Focko</last_name>
      <phone>﻿﻿+420567157676</phone>
      <email>fockot@nemji.cz</email>
    </contact>
    <investigator>
      <last_name>Peschout</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pärnu Hospital</name>
      <address>
        <city>Pärnu</city>
        <state>Pärnumaa</state>
        <zip>EE-80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator Kadri-Liina Vahula</last_name>
      <phone>+3724473500</phone>
      <email>kadri-liina.vahula@ph.ee</email>
    </contact>
    <investigator>
      <last_name>Kadri-Liina Vahula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital Womens Clinic</name>
      <address>
        <city>Tallin</city>
        <zip>10119</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator Inga Aavik</last_name>
      <phone>+3726067513</phone>
      <email>inga.aavik@itk.ee</email>
    </contact>
    <investigator>
      <last_name>Inga Aavik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator Terje Raud</last_name>
      <phone>+3727319993</phone>
      <email>terje.raud@kliinikum.ee</email>
    </contact>
    <investigator>
      <last_name>Terje Raud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius District Central Outpatient Clinic</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-01117</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Virginija Macioniene</last_name>
      <phone>﻿﻿+37068734385</phone>
      <email>virga.macioniene@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Teiberiene</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Davao Doctors Hospital</name>
      <address>
        <city>Davao City</city>
        <state>Davao Del Sur</state>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Angelito Dizon</last_name>
      <phone>﻿﻿+639338728885</phone>
      <email>thongdizon@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Rayel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perpetual Succour Hospital</name>
      <address>
        <city>Cebu</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Maria Lourdes Cipriano</last_name>
      <phone>﻿﻿+639175731262</phone>
      <email>marialourdes.cipriano@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Sulay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej Profimed</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-880</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study coordinator Monika Ochal</last_name>
      <phone>﻿﻿+48663586227</phone>
      <email>monika.ochal@profimed.lublin.pl</email>
    </contact>
    <investigator>
      <last_name>Nowakowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-880</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study coordinator Jan Kotarski</last_name>
      <phone>+48815327847</phone>
      <email>jan.kotarski@umlub.pl; jan.kotarski.gabinet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jan Kotarski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ginekologiczno-Polozniczy Szpital Kliniczny Uniwersytetu Medycznego w Poznaniu</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolskie</state>
        <zip>60-535</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator Marek Spaczynski</last_name>
      <phone>+48618419330</phone>
      <email>m.spaczynski@op.pl; m.spaczynski@op.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Spaczynski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Angelius Provita</name>
      <address>
        <city>Katowice</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator Mariusz Kiecka</last_name>
      <phone>+4832783730096</phone>
      <email>m.kiecka@angelius.org</email>
    </contact>
    <investigator>
      <last_name>Mariusz Kiecka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puerto Rico Translational Research Center (PRTRC)</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Janice Diaz Monge</last_name>
      <phone>(787) 759-0306</phone>
      <phone_ext>221</phone_ext>
      <email>janice.diaz2@upr.edu</email>
    </contact>
    <investigator>
      <last_name>Josefina Romaguera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MCM GYNPED, s.r.o.</name>
      <address>
        <city>Dubnica Nad Váhom</city>
        <zip>018 41</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primary Study Coordinator Michaela Vancova</last_name>
      <phone>﻿﻿+421911406561</phone>
      <email>michaela.vancova@srcsk.sk</email>
    </contact>
    <investigator>
      <last_name>Mokras</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Martin</name>
      <address>
        <city>Martin</city>
        <zip>036 59</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal investigator Jan Danko</last_name>
      <phone>﻿﻿+421434203242</phone>
      <email>danko@jfmed.uniba.sk</email>
    </contact>
    <investigator>
      <last_name>Jan Danko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lynette Reynders Private Practice</name>
      <address>
        <city>Centurion</city>
        <state>Gauteng</state>
        <zip>157</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study coordinator: Hestelle Roux</last_name>
      <phone>﻿﻿+27126640261</phone>
      <email>hgraaff@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Lynette Reynders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sub-Investigator Nomonde Hazel Mbatani</last_name>
      <phone>+27214044488</phone>
      <email>nomonde.mbatani@uct.ac.za</email>
    </contact>
    <investigator>
      <last_name>Denny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sanitas La Zarzuela</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study coordinator Isabel Carretero</last_name>
      <phone>﻿﻿+34915858053</phone>
      <email>icarretero@sanitas.es</email>
    </contact>
    <investigator>
      <last_name>Cristobal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study coordinator Martin Coronado</last_name>
      <phone>+34616563897</phone>
      <email>pcoronadom@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Martin Coronado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study coordinator Sasithorn Thong-In</last_name>
      <phone>﻿﻿+6622564241</phone>
      <email>sasikaew@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jaisamrarn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study coordinator Gessuda Chiravacharadej</last_name>
      <phone>﻿﻿+66816296582</phone>
      <email>gessuda.chi@mahidol.ac.th</email>
    </contact>
    <investigator>
      <last_name>Inthasorn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Lithuania</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.HPVReveal1.com</url>
    <description>Study Website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical intraepithelial neoplasia (CIN)</keyword>
  <keyword>Human papillomavirus (HPV)</keyword>
  <keyword>High grade squamous intraepithelial lesion (HSIL)</keyword>
  <keyword>CIN 2</keyword>
  <keyword>CIN 3</keyword>
  <keyword>papillomavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

